Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age

NEW YORK& MAINZ, Germany--(BUSINESS WIRE) February 11, 2022 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials